ACRS Aclaris Therapeutics Inc.

+0.33  (+5%)
Previous Close 6.41
Open 6.46
Price To Book 1.89
Market Cap 275909927
Shares 40,936,191
Volume 324,957
Short Ratio
Av. Daily Volume 561,564

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2Q 2019.
ATI-502 (AA-201 Topical) - dose ranging
Alopecia areata
Phase 2 open label data due 1H 2019.
ATI-502 (VITI-201 Topical)
Phase 2 trial ongoing.
ATI-502 AUATB-201 - open label
Alopecia areata - regrowth of eyebrows
Phase 2 data due 3Q 2019.
ATI-501 (AUAT-201 Oral)
Alopecia areata
Approval announced December 15, 2017.
ESKATA (hydrogen peroxide)
Seborrheic keratosis (SK)
Phase 3 data due 2H 2019.
A-101 THWART-1 and THWART-2
Common warts (verruca vulgaris)
Phase 2 interim data released June 28, 2018.
ATI-502 AA-202 Topical - PK/safety
Alopecia areata
Phase 2 data due 1H 2019.
ATI-502 - open label
Androgenetic alopecia (AGA) - Hair loss
Phase 2 data due mid-2019.
Atopic dermatitis (AD)

Latest News

  1. Aclaris Therapeutics to Present Scientific Posters at the 77th Annual Meeting of the American Academy of Dermatology
  2. Should You Worry About Aclaris Therapeutics, Inc.’s (NASDAQ:ACRS) CEO Salary Level?
  3. Aclaris Therapeutics to Attend Upcoming Investor Conferences
  4. Do Hedge Funds Love Aclaris Therapeutics, Inc. (ACRS)?
  5. Aclaris Therapeutics Enters Oversold Territory
  6. Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
  7. Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials
  8. Top 6 Performing IPOs of 2015 (ONCE, GBT)
  9. Aclaris Therapeutics Closes Acquisition of RHOFADE® (oxymetazoline hydrochloride) cream, 1% from Allergan
  10. Aclaris Therapeutics (ACRS) Enters Oversold Territory
  11. Report: Exploring Fundamental Drivers Behind Aclaris Therapeutics, Extreme Networks, Care, Air Lease, Globus Medical, and Heron Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments
  12. Edited Transcript of ACRS earnings conference call or presentation 6-Nov-18 10:00pm GMT
  13. Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
  14. Aclaris: 3Q Earnings Snapshot
  15. Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
  16. Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
  17. One Thing To Remember About The Aclaris Therapeutics Inc (NASDAQ:ACRS) Share Price